Antibodies against lif and dosage forms thereof

A method of treating an individual with cancer comprising administering to the individual a recombinant antibody that specifically binds Leukemia Inhibitory Factor (LIF) comprising:

• a) an immunoglobulin heavy chain complementarity determining region 1 (VH-CDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
• 1-3;
• b) an immunoglobulin heavy chain complementarity determining region 2 (VH-CDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
• 4 or 5;
• c) an immunoglobulin heavy chain complementarity determining region 3 (VH-CDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
• 6-8;
• d) an immunoglobulin light chain complementarity determining region 1 (VL-CDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
• 9 or 10;
• e) an immunoglobulin light chain complementarity determining region 2 (VL-CDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs:
• 11 or 12;
• and
• f) an immunoglobulin light chain complementarity determining region 3 (VL-CDR3) comprising an amino acid sequence set forth in SEQ ID NO:
• 13;
• wherein the recombinant antibody is administered to the individual at a dose from about 75 to about 2000 milligrams.